Fountain’s hormone-therapy page presents a kit and several payment periods. A kit is a convenient way to package an offer, but it is not a medicine identity. The word does not establish whether a proposed progesterone preparation is oral, topical, approved or compounded, and it does not turn several treatment components into one product with a shared evidence base.
We reviewed Fountain’s hormone-care page and terms on September 29, 2026. They establish an actual clinical service and describe financial commitments, while leaving the exact progesterone preparation open. This review follows the distinction between the commercial package, the clinician’s proposal and the pharmacy’s supplied medicine. No appointment, selected contract, prescription or delivery was tested.
Read this article by section
The kit names a treatment category before it identifies a product
Fountain’s hormone-care page names progesterone within its menopause offer. The reviewed description does not verify a specific oral micronized capsule or manufacturer. That matters because a kit can combine clinical access, medicine and support without revealing the details of every item. Our Lifeforce review looks at a different kind of name: a product page titled Micronized Progesterone. Neither title should be stretched beyond its documented detail. Fountain’s care offer is relevant to a consultation, but the proposed preparation still needs to be identified after the clinician determines what, if anything, is appropriate.
Progesterone is an ingredient name, not a complete route description
The published kit description does not supply enough information to assign a specific route to its progesterone component. An ingredient name cannot tell a reader whether a product is swallowed, applied to skin or used another way. Our route guide explains why those distinctions matter when interpreting evidence. Likewise, the progesterone and progestin guide separates names that are sometimes compressed into broad hormone language. A clinician should identify the intended medicine and purpose, not merely repeat the kit title. Nothing in the package presentation supports altering the instructions for a medicine that has already been prescribed.
Clinical responsibility and pharmacy choice are separate parts of the terms
Fountain’s terms, dated April 3, 2024, describe clinical services through independent medical groups and preserve professional judgment over prescribing. They also describe the ability to use a chosen pharmacy for a valid prescription. That pharmacy-choice statement does not establish that an outside pharmacy’s charge is included in the advertised kit price. Nor does it prove that every proposed preparation can be supplied by every pharmacy. A useful written clarification would identify the prescribing group, proposed medicine, intended dispensing arrangement and any effect on the package charge. The service platform, clinician and pharmacy have related but distinct responsibilities.
FDA approval belongs to a particular medicine, not the bundle
The FDA compounding explanation distinguishes compounded drugs from approved products. Fountain’s kit page does not resolve the regulatory category of the progesterone that an individual would receive. It would therefore be wrong to label the whole kit FDA approved, or to declare its progesterone compounded without product-specific support. The bioidentical approval guide shows why hormone identity cannot settle that issue. Clinical access and a prescription requirement also do not establish product approval. Ask for the exact preparation and its patient information so that the treatment discussion refers to a medicine rather than a purchasing label.
The three prices use weeks, not calendar months
The offer page lists Starter at $199 per four weeks, billed $199 every four weeks. Standard displays $167 per four weeks but bills $499 every twelve weeks. Pro displays $150 per four weeks with a $1,799 bill every forty-eight weeks. The full bills and their periods matter more than the shortened equivalents. Twelve weeks is not three calendar months, and forty-eight weeks is not a calendar year. These figures describe Fountain’s advertised package options, not a quote for a specified progesterone quantity. Confirm the selected agreement, included services, medicine arrangements and any additional charges before treating a displayed equivalent as the amount due. A bill covering several weeks should also be distinguished from the quantity of medicine supplied at one time. The listed payment period does not, by itself, establish the size of a progesterone package, its refill frequency or a clinician’s review schedule. Those details need separate confirmation in the selected offer and prescription. A longer prepayment period cannot be used as evidence that treatment is intended to remain unchanged throughout that period, because prescribing remains subject to the clinical decision described in the terms.
Renewal language is known; a personal refund outcome is not
Under the reviewed subscription terms, renewal continues unless cancellation occurs before the current period ends, with account closure at the period’s end. Those are documented conditions, so cancellation should not be described as wholly unknown. The outcome of a particular refund request and the terms of a selected agreement remain unverified. Our Alpha Hormones review examines a different cancellation notice period and refill process. Such differences concern the purchase relationship, not relative clinical value. Also separate support access from medical availability: advertising round-the-clock support does not establish a guaranteed response from a prescriber to an urgent medical concern.
Turn the package into three concrete questions
Before relying on a Fountain kit description, ask what the clinician is proposing, what the pharmacy would supply and what the selected payment agreement covers. The care page and terms provide different parts of those answers. A useful response would identify the actual progesterone route and formulation, the responsible professionals and the complete billing period. That level of detail would allow a more meaningful comparison than a kit name and a short price equivalent. This review confirms a clinical hormone-care offer with documented commitments; it does not verify a micronized product catalog, individual eligibility or the outcome of treatment.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Fountain: Hormone therapy for womenProvider clinical service and kit; full four-, twelve- and forty-eight-week billing periods retained, exact capsule unconfirmed · Checked 2026-09-29
- Fountain: Terms and conditionsProvider terms dated April 3, 2024; medical-group, prescription and pharmacy-choice clauses, not individual coverage or refund confirmation · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29